ArticleBone research2020
Aging and menopause reprogram osteoclast precursors for aggressive bone resorption.
Article in Bone research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.
- Identification of potential diagnostic and therapeutic apoptosis-related casual targets for osteoporosis: an integrated multi-omics analysis.Journal of bone and mineral metabolism · 2026Pooled it
- Efficacy of zoledronic acid in peri-menopausal women with osteopenia.Journal of bone and mineral metabolism · 2026Trial
- Immunosenescence and Bone Homeostasis: From Mechanisms of Homeostasis Disruption to Therapeutic Opportunities in Age-Related Skeletal Disorders.International journal of molecular sciences · 2026Review
- Epigenetic transcriptional regulation of skeletal aging: The emerging role of mJournal of orthopaedic translation · 2026Review
- Vitamin K-dependent carboxylation in osteoblasts regulates bone resorption through GAS6 in male mice.Bone research · 2026Article
- The Alamandine/MrgprD as a Key Player in Antiresorptive Effects in an Osteoporosis Experimental Model.Calcified tissue international · 2026Article
- Osteoimmune senescence in aging-related bone diseases.Frontiers in immunology · 2026Review
- Astragaloside IV modulates oxidative stress and osteoimmune-Wnt signaling in ovariectomized rats: an integrated study of RNA sequencing, molecular docking, and experimental validation.Frontiers in nutrition · 2026Article
- Heterogeneity in Lumbar Segmental Bone Mineral Density and Age-Related Evolution of Whole-Body Bone Mineral Density: Comprehensive Implications for Osteoporosis Risk Assessment.Orthopaedic surgery · 2026Article
- Regulation of Mitochondrial Homeostasis: Applications of Nanobiomaterials in Age-Related Bone Diseases.International journal of nanomedicine · 2026Review
- RANKL-convergent osteoimmune network framework in osteoporosis: integrating macrophage activation, T-cell imbalance, and cytokine crosstalk.Frontiers in immunology · 2026Review
- Cell fusion in osteoclastogenesis.Biochemical Society transactions · 2025Review
- A synbiotic medical food improves gut barrier function, reduces immune responses, and inhibits osteoclast activity in models of postmenopausal bone loss aligned with clinical outcomes.Journal of functional foods · 2025Article
- Biomaterials targeting senescent cells for bone regeneration: State-of-the-art and future perspectives.Bioactive materials · 2025Review
- From Development, Disease, and Decline: A Review of What Defines an Osteoclast Progenitor.International journal of molecular sciences · 2025Review
- Comparative analysis of osteoclast function in symptomatic and asymptomatic individuals with cherubism-causing SH3BP2 mutation.JBMR plus · 2025Article
- Non-coding RNA modulation in osteoclasts and its implications for osteoblast lineage cell behavior in a co-culture system.Cell communication and signaling : CCS · 2025Article
- Cathepsin K inhibitors promote osteoclast-osteoblast communication and engagement of osteogenesis.JBMR plus · 2025Article
- Cabozantinib, an Anti-Aging Agent, Prevents Bone Loss in Estrogen-Deficient Mice by Suppressing Senescence-Associated Secretory Phenotype Factors.International journal of molecular sciences · 2025Article
- Elevated sclerostin levels contribute to reduced bone mineral density in non-ambulatory stroke patients.Bone reports · 2025Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Women gradually lose bone from the age of ~35 years, but around menopause, the rate of bone loss escalates due to increasing bone resorption and decreasing bone formation levels, rendering these individuals more prone to developing osteoporosis. The increased osteoclast activity has been linked to a reduced estrogen level and other hormonal changes. However, it is unclear whether intrinsic changes in osteoclast precursors around menopause can also explain the increased osteoclast activity. Therefore, we set up a protocol in which CD14
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.